Cell-cycle fate-monitoring distinguishes individual chemosensitive and chemoresistant cancer cells in drug-treated heterogeneous populations demonstrated by real-time FUCCI imaging

Cell Cycle. 2015;14(4):621-9. doi: 10.4161/15384101.2014.991604.

Abstract

Essentially every population of cancer cells within a tumor is heterogeneous, especially with regard to chemosensitivity and resistance. In the present study, we utilized the fluorescence ubiquitination-based cell cycle indicator (FUCCI) imaging system to investigate the correlation between cell-cycle behavior and apoptosis after treatment of cancer cells with chemotherapeutic drugs. HeLa cells expressing FUCCI were treated with doxorubicin (DOX) (5 μM) or cisplatinum (CDDP) (5 μM) for 3 h. Cell-cycle progression and apoptosis were monitored by time-lapse FUCCI imaging for 72 h. Time-lapse FUCCI imaging demonstrated that both DOX and CDDP could induce cell cycle arrest in S/G2/M in almost all the cells, but a subpopulation of the cells could escape the block and undergo mitosis. The subpopulation which went through mitosis subsequently underwent apoptosis, while the cells arrested in S/G2/M survived. The present results demonstrate that chemoresistant cells can be readily identified in a heterogeneous population of cancer cells by S/G2/M arrest, which can serve in future studies as a visible target for novel agents that kill cell-cycle-arrested cells.

Keywords: FUCCI; GFP; HeLa; RFP; cancer; cell cycle; chemoresistance; chemosensitivity; cisplatinum; doxorubicin; time-lapse imaging; tumor heterogeneity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Apoptosis / physiology*
  • Cell Cycle / drug effects
  • Cell Cycle / physiology*
  • Cell Lineage / physiology*
  • Cisplatin
  • Doxorubicin
  • HeLa Cells
  • Humans
  • Mitosis / physiology
  • Neoplasms / drug therapy
  • Neoplasms / physiopathology*
  • Optical Imaging / methods*
  • Proportional Hazards Models
  • Time-Lapse Imaging / methods

Substances

  • Antineoplastic Agents
  • Doxorubicin
  • Cisplatin